Demand pull is outrunning the plan for one still-small offering, and the company is visibly re-pointing itself at it
The model's full reasoning — Q3 2021 call → NOWe need to determine if management describes an identifiable offering/initiative that is still small relative to the company's total business, with both: (1) customer response running ahead of what company prepared for, and (2) company responding now by putting more behind it. The transcript mentions Brave Care investment and pediatric clinics. Mark Ordan says: "we recently announced our investment in Brave Care... we have a nucleus from which we can grow. But for this to grow, we needed the engine and the talent... Brave Care brings scalable internal controls and patient-facing technology... The proprietary technology systems and operating platform that Brave's team has built... gives patients and their parents a truly seamless experience... It also gives Brave remote connectivity to clinicians... Brave Care systems are integrated with all facets of clinical operations. And my view of the power of the Brave system is not theoretical. It's proven and up and running in their existing clinics in the Northwest. Our investment in Brave the company by an operating partnership agreement that provides Brave a long-term incentives to help us plan, develop, equip, and open pediatric clinics over the coming years. The clinic will be ours, and will be led and managed by our team working alongside the Brave team. At a high level, looking at our geography of existing services, we believe that there's an opportunity for us to open more than 100 pediatric clinics across our footprint within a few years and as we move forward, we'll share with you how this will materialize. We believe that our growth will include both de novo development and acquisitions, and we're already in discussions with certain existing platforms that we think overlap well with us and they can integrate into our strategic growth." This describes an initiative: pediatric clinics (urgent care? primary care?) using Brave Care technology. Is it small relative to total business? Yes, it's a new venture. But does management describe customer response running ahead of what they prepared for? They say "It's proven and up and running in their existing clinics in the Northwest." But they don't say that demand is exceeding expectations or that they are scrambling to keep up. They say they are planning to open more than 100 clinics, but that's future.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| ROCK | Gibraltar Industries, Inc. | Q1 2024 | 2024-05-01 | B+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
HCKT · Q1 2024 → YESThe question is about whether management describes one identifiable offering that's still small, where customer response is ahead of what they prepared for, AND they're responding now by putting more ...YES The transcript describes AI Explorer (the GenAI assessment platform) as a small, early-stage offering (nominal Q1 revenue impact, part of broader GenAI pivot). Management states customer response is exceeding preparation: "over 175 demo meetings with many more scheduled... resulted in a number of new enterprise...
SYY · Q1 2023 → YESThe question is about whether management describes one identifiable offering or initiative that's still a smaller part of the business, where customer response is running ahead of what they prepared f...YES The transcript shows that Sysco Your Way is presented as a smaller, still-developing offering (described as part of the Recipe For Growth pillars, with its scale expected to grow each quarter and currently limited to specific neighborhoods and recent international rollouts like Toronto and Dublin).
PRPH · Q1 2023 → YESThe question asks if management describes one identifiable offering that's still a smaller part of the business, where customer response is running ahead of what they prepared for, AND they're respond...YES The lozenge manufacturing facility is the clearest match. It is explicitly described as “the least interesting business we’re developing” and still a smaller slice of overall results (COVID testing was the dominant revenue driver for the prior two years).